<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="afa14bda-c9ec-485c-527a-622d0afb457a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">INTROVALE</content> safely and effectively. See full prescribing information for <content styleCode="bold">INTROVALE</content>.<br/> <br/>
      <content styleCode="bold">INTROVALE<sup>®</sup> (levonorgestrel and ethinyl estradiol) tablets, for oral use</content>
      <br/>Initial U.S. Approval: 1982</title>
   <effectiveTime value="20241015"/>
   <setId root="24abb5e1-5be4-87e7-404c-d8c2db25ffd0"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080228637" root="1.3.6.1.4.1.519.1"/>
            <name>Xiromed LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="080228637" root="1.3.6.1.4.1.519.1"/>
                  <name>Xiromed LLC</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5514a190-4cb1-ac7b-2b86-bfaf9101d6af"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241015"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="70700-208"/>
                        <name>INTROVALE</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levonorgestrel and Ethinyl Estradiol tablets</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="70700-208-87"/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="3"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code codeSystem="2.16.840.1.113883.6.69" code="70700-208-88"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250129"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="84"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="70700-855"/>
                              <name>Levonorgestrel and Ethinyl Estradiol</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Levonorgestrel and Ethinyl Estradiol</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="0.03"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETHINYL ESTRADIOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ETHINYL ESTRADIOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="0.15"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="5W7SIA7YZW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVONORGESTREL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="5W7SIA7YZW" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LEVONORGESTREL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0BZ5A00FQU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLACRILIN POTASSIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA200490" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250129"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                                    <originalText>white to off-white</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="6" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                                    <originalText>round</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">212</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="70700-856"/>
                              <name>Inert</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Inert</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE YELLOW</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0BZ5A00FQU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLACRILIN POTASSIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA200490" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250129"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48329" displayName="GREEN" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="6" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">279</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA200490" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250129"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_dcf98049-83de-4597-9cb2-d777f5b0d2ee">
               <id root="3c8912ce-f035-2016-0343-28b7013f748f"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Introvale, are contraindicated in women who are over 35 years of age and smoke <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml> and <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <paragraph>
                                 <content styleCode="bold">Introvale is contraindicated in women over 35 years old who smoke. (<linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">4</linkHtml>)</content>
                              </paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. (<linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">5.1</linkHtml>)</content>
                              </paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_2922495b-dffa-40a0-a6db-5af1e72a558f">
               <id root="d9922aaa-3218-e129-55f6-6b69e1b7f9e8"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Introvale is indicated for use by females of reproductive potential to prevent pregnancy.</paragraph>
               </text>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>Introvale is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. (<linkHtml href="#ID_2922495b-dffa-40a0-a6db-5af1e72a558f">1</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_f612316a-3ced-4a39-ad3f-76baeb5cd9b0">
               <id root="9d99812f-acdc-ec55-c0be-427bf83cab11"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>Take one tablet daily by mouth at the same time every day for 91 days. (<linkHtml href="#ID_a3cbce58-33da-4eb7-800a-198a65a51b61">2.1</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Take tablets in the order directed on the Extended-Cycle Blister Pack. (<linkHtml href="#ID_501dd330-0842-4fa8-afa7-0b920f22951f">2.2</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_a3cbce58-33da-4eb7-800a-198a65a51b61">
                     <id root="7b71fb17-9622-97b8-ccd0-4dd7842a6856"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 How to Start and Take Introvale</title>
                     <text>
                        <paragraph>Introvale is dispensed in an Extended-Cycle Blister Pack [<content styleCode="italics">see <linkHtml href="#ID_0bf2bba3-7eaa-468e-93b1-eb164a24ed25">How Supplied/Storage and Handling (16)</linkHtml>
                           </content>]. Introvale should be started on a Sunday (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.</paragraph>
                        <table width="100%">
                           <caption>Table 1: Instructions for Administration of Introvale</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Starting Introvale in females with no current use of hormonal contraception (Sunday Start)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Important:</content>
                                    </paragraph>
                                    <paragraph>Consider the possibility of ovulation and conception prior to initiation of this product.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Tablet Color:</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>Introvale active tablets are white to off-white (Day 1 to Day 84).</paragraph>
                                       </item>
                                       <item>
                                          <paragraph>Introvale inactive tablets are green (Day 85 to Day 91).</paragraph>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Sunday Start:</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">For each 91-day course, take in the following order:</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>Take the first <content styleCode="bold">white to off-white </content>tablet (0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol) on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, take the tablet on that day. <content styleCode="bold">Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms or spermicide) for the first 7 days of treatment.</content>
                                          </paragraph>
                                       </item>
                                       <item>
                                          <paragraph>Take subsequent white to off-white tablets once daily at the same time each day for a total of 84 days.</paragraph>
                                       </item>
                                       <item>
                                          <paragraph>Take one <content styleCode="bold">green </content>tablet (inert) daily for the following 7 days and at the same time of day that active tablets were taken. A scheduled period should occur during the 7 days that the green tablets are taken.</paragraph>
                                       </item>
                                       <item>
                                          <paragraph>Begin the next and all subsequent 91-day courses of Introvale without interruption on the same day of the week (Sunday) on which the patient began her first dose. Follow the same schedule as the initial 91-day course: a white to off-white tablet once a day for 84 days, and a green tablet once a day for 7 days. If the patient does not immediately start her next pill pack, instruct her to protect herself from pregnancy by using a non-hormonal back-up method of contraception until she has taken a white to off-white tablet daily for 7 consecutive days.</paragraph>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Switching from another contraceptive method to Introvale</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Start Introvale:</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Another oral contraceptive</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>On the day when the new pack of the previous COC would have been started</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Transdermal patch</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>On the day when the next application would have been scheduled.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Vaginal ring</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>On the day when the next insertion would have been scheduled.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Injection</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>On the day when the next injection would have been scheduled.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Intrauterine contraceptive (IUD)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>On the day of removal.</paragraph>
                                       </item>
                                       <item>
                                          <paragraph>If the IUD is not removed on first day of the patient’s menstrual cycle, additional non-hormonal contraception (such as condoms or spermicide) is needed for the first seven days of the first 91-day course.</paragraph>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Implant</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>On the day of removal.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_7f0f913d-6f1c-4a44-a3d4-eabb51bf9790">
                           <id root="55aa77ca-2c12-d6a4-88a8-958639965741"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="underline">Starting Introvale after Abortion or Miscarriage</content>
                              </content>
                           </title>
                           <effectiveTime value="20240715"/>
                           <component>
                              <section ID="ID_603e8e88-ca2a-4b14-a4fc-09d2ed41ce32">
                                 <id root="b56a687e-9706-750f-68cd-91059f4e64ac"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>
                                    <content styleCode="bold">First-trimester</content>
                                    <content styleCode="bold"/>
                                 </title>
                                 <text>
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>After a first-trimester abortion or miscarriage, Introvale may be started immediately. An additional method of contraception is not needed if Introvale is started immediately.</paragraph>
                                       </item>
                                       <item>
                                          <paragraph>If Introvale is not started within 5 days after termination of the pregnancy, the patient should use additional non-hormonal contraception (such as condoms or spermicide) for the first seven days of her first 91-day course of Introvale.</paragraph>
                                       </item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20240715"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_90957597-90be-4be7-98be-7b0b45c87893">
                                 <id root="913fa42d-aba1-1215-1eb2-e570f8f25b18"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>
                                    <content styleCode="bold">Second-trimester</content>
                                    <content styleCode="bold"/>
                                 </title>
                                 <text>
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>Do not start Introvale until 4 weeks after a second-trimester abortion or miscarriage, due to the increased risk of thromboembolic disease. Start Introvale following the instructions in Table 1 for Sunday start. Use additional non-hormonal contraception (such as condoms or spermicide) for the first seven days of the patient’s first 91-day course of Introvale <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>,<linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>].</content>
                                          </paragraph>
                                       </item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20240715"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_53eb827d-9b3c-4bb8-846e-f4bd5c0d0946">
                           <id root="49d20b20-2f9d-6522-3cfa-9a2d704b1156"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="underline">Starting Introvale after Childbirth</content>
                              </content>
                           </title>
                           <text>
                              <list listType="unordered">
                                 <item>
                                    <paragraph>Do not start Introvale until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with Introvale following the instructions in Table 1 for women not currently using hormonal contraception.</paragraph>
                                 </item>
                                 <item>
                                    <paragraph>Introvale is not recommended for use in lactating women <content styleCode="italics">[see <linkHtml href="#ID_c65b9b36-8eaa-4097-8082-bfc00ae846de">Use in Specific Populations (8.2)</linkHtml>].</content>
                                    </paragraph>
                                 </item>
                                 <item>
                                    <paragraph>If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of Introvale <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>, <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#ID_f243fee4-987a-4281-b7d5-692266d4f09d">Use in Specific Populations (8.1</linkHtml> and <linkHtml href="#ID_c65b9b36-8eaa-4097-8082-bfc00ae846de">8.2)</linkHtml>].</content>
                                    </paragraph>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_501dd330-0842-4fa8-afa7-0b920f22951f">
                     <id root="f2bbd3db-dd8b-8697-3505-a4bded2d7d74"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Dosing Introvale</title>
                     <text>
                        <paragraph>Instruct patients to take one tablet by mouth at the same time every day. The dosing of Introvale is one white to off-white pill containing levonorgestrel and ethinyl estradiol daily for 84 consecutive days, followed by one green pill (inactive pills without hormone) for 7 days. To achieve maximum contraceptive effectiveness, Introvale must be taken exactly as directed, in the order directed on the Blister Pack, and at intervals not exceeding 24 hours. Start taking the first white to off-white pill from a new Blister Pack the very next day after taking the last green inactive pill in the Blister Pack. The failure rate may increase when pills are missed or taken incorrectly.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_19f47927-4b29-47e5-8b28-c9f3b228f38a">
                     <id root="19253ea5-9e67-2c65-0803-7917e7e7fe26"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 	Missed Doses </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <table cellpadding="0pt" width="100%">
                           <caption>Table 2: Instructions for Missed Introvale Tablets</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>If one active tablet (white to off-white) is missed in Days 1 through 84</paragraph>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>Take the tablet as soon as possible. Take the next tablet at the regular time and continue taking one tablet a day until the 91-day course is finished.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>If two consecutive active tablets (white to off-white) are missed in Days 1 through 84</paragraph>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>Take 2 tablets on the day remembered and 2 tablets the next day. Then continue taking one tablet a day until the 91-day course is finished.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Additional non-hormonal contraception (such as condoms or spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets.</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>If three or more consecutive active tablets (white to off-white) are missed in Days 1 through 84</paragraph>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>Do not take the missed tablets. Continue taking one tablet a day until the 91-day course is finished. <content styleCode="bold">Additional non-hormonal contraception (such as condoms or spermicide) must be used as back-up if the patient has sex within 7 days after missing tablets.</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>If any of the seven green (inactive) tablets are missed</paragraph>
                                       </item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>Throw away the missed tablets. Continue taking the remaining tablets until the pack is finished. A backup birth control method is not needed.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_904be13c-331f-420f-9249-15f3031ad148">
                     <id root="0b0146a5-e38c-905f-1564-587022799671"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 	Advice in Case of Gastrointestinal Disturbances  </title>
                     <text>
                        <paragraph>In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken. If vomiting or diarrhea occurs within 3-4 hours after taking a white to off-white tablet, handle this as a missed tablet. </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a1531931-c0cb-44ef-9a83-b80f76719836">
               <id root="8df9acc6-aa09-17d5-1eb5-4049f8f1f655"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Introvale is available as round, biconvex, unscored tablets, packaged in a carton of 3 pouches, each pouch contains Extended-Cycle Tablet Blister Pack of 91 tablets, each containing a 13-week supply of tablets in the following order:</paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>84 white to off-white tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol; debossed with <content styleCode="bold">212</content> on the one side and plain on the other side</paragraph>
                     </item>
                     <item>
                        <paragraph>7 green inert tablets debossed with <content styleCode="bold">279</content> on the one side and plain on the other side.</paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>Introvale consists of 84 round, white to off-white tablets containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and 7 round, green inert tablets. (<linkHtml href="#ID_a1531931-c0cb-44ef-9a83-b80f76719836">3</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">
               <id root="5a86752d-6f0c-dfa4-a199-d6217ee3de8b"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Introvale is contraindicated in females who are known to have or develop the following conditions:</paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>A high risk of arterial or venous thrombotic diseases. Examples include females who are known to:</paragraph>
                        <list listType="unordered">
                           <item>
                              <paragraph>Smoke, if over age 35 <content styleCode="italics">[see <linkHtml href="#ID_dcf98049-83de-4597-9cb2-d777f5b0d2ee">Boxed Warning</linkHtml> and <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have current or history of deep vein thrombosis or pulmonary embolism <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have cerebrovascular disease <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have coronary artery disease <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have inherited or acquired hypercoagulopathies <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have uncontrolled hypertension or hypertension with vascular disease <content styleCode="italics">[see <linkHtml href="#ID_076f26f3-f622-4cdb-8397-0a9d4e9bd89a">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have diabetes mellitus and are over age of 35, diabetes mellitus with hypertension or vascular disease or other end-organ damage, or diabetes mellitus of &gt; 20 years duration <content styleCode="italics">[see <linkHtml href="#ID_fdc2c486-e90a-4673-bc93-edb4bc3d552b">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                           </item>
                           <item>
                              <paragraph>Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches <content styleCode="italics">[see <linkHtml href="#ID_a5753a4f-1f60-414b-af0e-2427b252a6ed">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <paragraph>Current diagnosis of, or history of breast cancer, which may be hormone sensitive <content styleCode="italics">[see <linkHtml href="#ID_8875c157-10e1-42ef-8a24-40d91fe8ebfa">Warnings and Precautions (5.11)</linkHtml>]. </content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis <content styleCode="italics">[see <linkHtml href="#ID_c2d59193-5664-4c2d-9d45-37dc47ef723e">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#ID_b040c6ef-c716-42df-b060-58366b89a3bc">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                     </item>
                     <item>
                        <paragraph>Undiagnosed abnormal uterine bleeding <content styleCode="italics">[see <linkHtml href="#ID_dec4fdbc-96f8-44b8-ae0a-6d0a8c69f31a">Warnings and Precautions (5.9)</linkHtml>]</content>.</paragraph>
                     </item>
                     <item>
                        <paragraph>Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations <content styleCode="italics">[see <linkHtml href="#ID_37935806-ae24-4806-ad81-1f2f4498f8ba">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>A high risk of arterial or venous thrombotic diseases (<linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Liver tumors or liver disease, acute viral hepatitis or decompensated cirrhosis (<linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Undiagnosed abnormal uterine bleeding (<linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Breast cancer (<linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ ritonavir, with or without dasabuvir. (<linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">4</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_d44489df-378e-4dd7-b293-49597f75268c">
               <id root="8122d48d-3534-ec79-9d02-dac60bec310b"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>Vascular risks: Stop if a thrombotic or thromboembolic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years. (<linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">5.1</linkHtml>, <linkHtml href="#ID_68e0dc43-3123-4443-b8ba-48e5595f2e03">5.5</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Liver disease: Discontinue if jaundice occurs. (<linkHtml href="#ID_c2d59193-5664-4c2d-9d45-37dc47ef723e">5.2</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Hypertension: If used in women with well-controlled hypertension, monitor blood pressure and stop if blood pressure rises significantly. (<linkHtml href="#ID_076f26f3-f622-4cdb-8397-0a9d4e9bd89a">5.4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Gallbladder disease: May cause or worsen gallbladder disease. (<linkHtml href="#ID_68e0dc43-3123-4443-b8ba-48e5595f2e03">5.5</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Adverse carbohydrate and lipid effects: Monitor glucose in prediabetic and diabetic women taking levonorgestrel and ethinyl estradiol tablets. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia. (<linkHtml href="#ID_fdc2c486-e90a-4673-bc93-edb4bc3d552b">5.7</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Headache: Evaluate significant change in headaches and discontinue if indicated. (<linkHtml href="#ID_a5753a4f-1f60-414b-af0e-2427b252a6ed">5.8</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Uterine bleeding: May cause irregular bleeding or amenorrhea. Evaluate for other causes if symptoms persist. (<linkHtml href="#ID_dec4fdbc-96f8-44b8-ae0a-6d0a8c69f31a">5.9</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_14261716-6488-49a1-9bee-201941549417">
                     <id root="1b7127c2-b681-ebcf-e4a7-13a080735479"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1	Thromboembolic Disorders and Other Vascular Conditions  </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>Stop levonorgestrel and ethinyl estradiol tablets if an arterial or venous thrombotic/thromboembolic event occurs.</paragraph>
                           </item>
                           <item>
                              <paragraph>Stop levonorgestrel and ethinyl estradiol tablets if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.</paragraph>
                           </item>
                           <item>
                              <paragraph>Discontinue levonorgestrel and ethinyl estradiol tablets during prolonged immobilization. If feasible, stop levonorgestrel and ethinyl estradiol tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism.</paragraph>
                           </item>
                           <item>
                              <paragraph>Start levonorgestrel and ethinyl estradiol tablets no earlier than 4 weeks after delivery in females who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week.</paragraph>
                           </item>
                           <item>
                              <paragraph>Before starting levonorgestrel and ethinyl estradiol tablets evaluate any past medical history or family history of thrombotic or thromboembolic disorders and consider whether the history suggests an inherited or acquired hypercoagulopathy. Levonorgestrel and ethinyl estradiol tablets are contraindicated in females with a high risk of arterial or venous thrombotic/thromboembolic diseases <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>.</paragraph>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_6478ef47-8775-4188-90bc-1ccaac27e5e3">
                           <id root="3b870a5c-df2e-19ce-875e-0bd3c45677d2"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Arterial Events</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>COCs increase the risk of cardiovascular events and cerebrovascular events, such as myocardial infarction and stroke. The risk is greater among older women (&gt;35 years of age), smokers, and females with hypertension, dyslipidemia, diabetes, or obesity.</paragraph>
                              <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in women over 35 years of age who smoke <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_5469c722-c40f-4ac1-b8be-9abad7d8a181">
                           <id root="b7c6581f-8ffc-1a84-615f-be046747191c"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Venous Events</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>. While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years. </paragraph>
                              <paragraph>The risk of VTE is highest during the first year of use of a COC and when restarting hormonal contraception after a break of four weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after COC use is discontinued. </paragraph>
                              <paragraph>Figure 1 shows the risk of developing a VTE for females who are not pregnant and do not use oral contraceptives, for females who use oral contraceptives, for pregnant females and for females in the postpartum period. To put the risk of developing a VTE into perspective: If 10,000 females who are not pregnant and do not use oral contraceptives are followed for one year, between 1 and 5 of these females will develop a VTE.</paragraph>
                              <paragraph>Figure 1: Likelihood of Developing a VTE</paragraph>
                              <renderMultiMedia ID="id-2074814176" referencedObject="ID_0083da55-45e2-4d87-9532-4e9625d01744"/>
                              <paragraph>Use of levonorgestrel and ethinyl estradiol tablets provides women with more hormonal exposure on a yearly basis than conventional monthly COCs containing the same strength synthetic estrogens and progestins (an additional 9 weeks of exposure per year). In the clinical trial, one case of pulmonary embolism was reported. Postmarketing adverse reactions of VTE have been reported in women who used levonorgestrel and ethinyl estradiol tablets.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                           <component>
                              <observationMedia ID="ID_0083da55-45e2-4d87-9532-4e9625d01744">
                                 <text>Figure 1: Likelihood of Developing a VTE</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="image-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_c2d59193-5664-4c2d-9d45-37dc47ef723e">
                     <id root="69fb44c1-2dc7-098e-6268-6a624839030f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2	Liver Disease  </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_e813de38-d152-46c8-b09e-5e1570731354">
                           <id root="4210d2bd-b230-d7dd-dd50-4e6d3d06b92e"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Elevated Liver Enzymes</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in females with acute viral hepatitis or severe (decompensated) cirrhosis of the liver <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>. Acute liver test abnormalities may necessitate the discontinuation of levonorgestrel and ethinyl estradiol tablets until the liver tests return to normal and levonorgestrel and ethinyl estradiol tablets causation has been excluded. Discontinue levonorgestrel and ethinyl estradiol tablets if jaundice develops. </paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_08287138-dcf2-45a8-be37-aadeee62fced">
                           <id root="e2dc603d-9d91-2771-41be-97e107489042"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Liver Tumors</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in females with benign and malignant liver tumors <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>. COCs increase the risk of hepatic adenomas. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. </paragraph>
                              <paragraph>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt; 8 years) COC users. The attributable risk of liver cancers in COC users is less than one case per million users.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_37935806-ae24-4806-ad81-1f2f4498f8ba">
                     <id root="213bc3b5-bb05-68cb-4551-0f54f1cd26be"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment  </title>
                     <text>
                        <paragraph>During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as levonorgestrel and ethinyl estradiol tablets. Discontinue levonorgestrel and ethinyl estradiol tablets prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>. Levonorgestrel and ethinyl estradiol tablets can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_076f26f3-f622-4cdb-8397-0a9d4e9bd89a">
                     <id root="2b685350-84df-be59-4188-3dabdf6695d0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Hypertension</title>
                     <text>
                        <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in females with uncontrolled hypertension or hypertension with vascular disease <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>].</content> For all women, including those with well-controlled hypertension, monitor blood pressure at routine visits and stop levonorgestrel and ethinyl estradiol tablets if blood pressure rises significantly.</paragraph>
                        <paragraph>An increase in blood pressure has been reported in females taking COCs, and this increase is more likely in older women and with extended duration of use. The effect of COCs on blood pressure may vary according to the progestin in the COC.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_68e0dc43-3123-4443-b8ba-48e5595f2e03">
                     <id root="d634fc12-1c4f-2ede-6875-d57245066b32"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Age-related Considerations </title>
                     <text>
                        <paragraph>The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml> and <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating levonorgestrel and ethinyl estradiol tablets for women over 35 years, such as: </paragraph>
                        <list listType="unordered">
                           <item>
                              <paragraph>Hypertension</paragraph>
                           </item>
                           <item>
                              <paragraph>Diabetes</paragraph>
                           </item>
                           <item>
                              <paragraph>Dyslipidemia</paragraph>
                           </item>
                           <item>
                              <paragraph>Obesity</paragraph>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f831dd1b-aa4a-4204-b25c-1984e86fbf8a">
                     <id root="c00d22c2-08bd-fc80-62a8-d3fa83fc9839"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6	Gallbladder Disease  </title>
                     <text>
                        <paragraph>Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including levonorgestrel and ethinyl estradiol tablets, may worsen existing gallbladder disease.</paragraph>
                        <paragraph>A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Females with a history of pregnancy-related cholestasis may be at an increased risk for COC-related cholestasis. </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fdc2c486-e90a-4673-bc93-edb4bc3d552b">
                     <id root="039914e6-813e-746f-6875-056de30cbaa4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Adverse Carbohydrate and Lipid Metabolic Effects </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_321e193a-0cfb-4e52-bb50-f58d225bd0f2">
                           <id root="94af5b6f-5041-ce2b-e993-ec0ea9ccb3e6"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Hyperglycemia</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in diabetic women over age 35, or females who have diabetes with hypertension, nephropathy, retinopathy, neuropathy, other vascular disease or females with diabetes of &gt; 20 years of duration <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>. Levonorgestrel and ethinyl estradiol tablets may decrease glucose tolerance. Carefully monitor prediabetic and diabetic females who are using levonorgestrel and ethinyl estradiol tablets.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_302e6129-2a8c-4ec1-ad8f-1d04c0aed525">
                           <id root="36134f88-4441-eac7-b5a2-c7b693f8bb37"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Dyslipidemia</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Consider alternative contraception for females with uncontrolled dyslipidemia. Levonorgestrel and ethinyl estradiol tablets may cause adverse lipid changes.</paragraph>
                              <paragraph>Females with hypertriglyceridemia, or a family history thereof, may have an increase in serum triglyceride concentrations when using levonorgestrel and ethinyl estradiol tablets, which may increase the risk of pancreatitis.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_a5753a4f-1f60-414b-af0e-2427b252a6ed">
                     <id root="c6aafd1b-660e-730b-5840-5b3ccd18117d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Headache </title>
                     <text>
                        <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in females who have headaches with focal neurological symptoms or have migraine headaches with aura, and in women over age 35 years who have migraine headaches with or without aura <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>.</paragraph>
                        <paragraph>If a female taking levonorgestrel and ethinyl estradiol tablets develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue levonorgestrel and ethinyl estradiol tablets if indicated. Consider discontinuation of levonorgestrel and ethinyl estradiol tablets if there is an increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dec4fdbc-96f8-44b8-ae0a-6d0a8c69f31a">
                     <id root="fcc6cbeb-7ac5-adce-efee-ec715a1d94bf"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9	Bleeding Irregularities and Amenorrhea  </title>
                     <text>
                        <paragraph>Bleeding and/or spotting that occurs at any time while taking the first 84 tablets of each extended-cycle regimen is considered “unscheduled” bleeding/spotting. Bleeding that occurs during the time a woman takes the seven green inert tablets is considered “scheduled” bleeding.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_ba4c2473-b53c-47b6-a0ad-9f9d7ed53a2a">
                           <id root="32f0bfe3-dc6f-8d0b-5613-5b98e3e0435a"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Unscheduled Bleeding and Spotting</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Females using levonorgestrel and ethinyl estradiol tablets may experience unscheduled (breakthrough or intracyclic) bleeding and spotting especially during the first 3 months of use. Bleeding irregularities may resolve over time or by changing to a different contraceptive product. If unscheduled bleeding persists or occurs after previously regular cycles, evaluate for causes such as pregnancy or malignancy.</paragraph>
                              <paragraph>Before prescribing levonorgestrel and ethinyl estradiol tablets, advise the woman to weigh the occurrence of fewer scheduled menses (4 per year instead of 13 per year) against the occurrence of increased unscheduled bleeding and/or spotting.</paragraph>
                              <paragraph>The clinical trial of the efficacy of levonorgestrel and ethinyl estradiol tablets (91-day cycles) in preventing pregnancy also assessed scheduled and unscheduled bleeding. The participants in the study were composed primarily of women who had used oral contraceptives previously as opposed to new users. Women with a history of breakthrough bleeding/spotting ≥ 10 consecutive days on oral contraceptives were excluded from the study. More levonorgestrel and ethinyl estradiol tablets subjects, compared to subjects on the comparator 28-day cycle regimen, discontinued prematurely for unacceptable bleeding (7.7% [levonorgestrel and ethinyl estradiol tablets] vs. 1.8% [28-day cycle regimen]).</paragraph>
                              <paragraph>Unscheduled bleeding and unscheduled spotting decreased over successive 91-day cycles. Table 3 below presents the number of days with unscheduled bleeding and/or spotting for each respective 91-day cycle.</paragraph>
                              <table width="100%">
                                 <caption>Table 3: Number of Unscheduled Bleeding and/or Spotting Days per 91-day Cycle</caption>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="6" styleCode="Botrule" valign="top">Q1=Quartile 1: 25% of women had ≤ this number of days of unscheduled bleeding/spotting Median: 50% of women had ≤ this number of days of unscheduled bleeding/spotting Q3=Quartile 3: 75% of women had ≤ this number of days of unscheduled bleeding/spotting</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Cycle (N)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" colspan="4" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Days of Unscheduled Bleeding and/or Spotting per 84-Day Interval</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Median Days Per Subject-</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">Month</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Mean</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Q1</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Median</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Q3</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>1 (446)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>15.1</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>3.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>12</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>23.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>3.0</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>2 (368)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>11.6</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>2.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>6</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>17.5</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>1.5</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>3 (309)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>10.6</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>1.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>6</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>15.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>1.5</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>4 (282)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>8.8</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>1.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>4</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>14.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>1.0</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Table 4 shows the percentages of women with ≥ 7 days and ≥ 20 days of unscheduled spotting and/or bleeding in the levonorgestrel and ethinyl estradiol tablets and the 28-day cycle treatment groups.</paragraph>
                              <table width="100%">
                                 <caption>Table 4: Percentage of Subjects with Unscheduled Bleeding and/or Spotting</caption>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>Days of unscheduled bleeding and/or spotting</paragraph>
                                       </td>
                                       <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>Percentage of Subjects<sup>a</sup>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">Levonorgestrel and Ethinyl Estradiol Tablets</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>Cycle 1 (N=385)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>Cycle 4 (N=261)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>≥ 7 days</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>65%</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>42%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>≥ 20 days</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>35%</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>15%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>
                                             <content styleCode="bold">28-day regimen</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>Cycles 1-4 (N=194)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>Cycles 10-13 (N=158)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="middle">
                                          <paragraph>≥ 7 days</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>38%</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                          <paragraph>39%</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>≥ 20 days</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>6%</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>4%</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <sup>a</sup>Based on spotting and/or bleeding on days 1-84 of a 91 day cycle in the levonorgestrel and ethinyl estradiol tablets subjects and days 1-21 of a 28 day cycle over 4 cycles in the 28-day dosing regimen.</paragraph>
                              <paragraph>Total days of bleeding and/or spotting (scheduled plus unscheduled) were similar over one year of treatment for levonorgestrel and ethinyl estradiol tablets subjects and subjects on the 28-day cycle regimen.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_2002dd6d-9140-4dc1-89e8-30fff06a2495">
                           <id root="f66df88a-564d-1285-8ce5-1a7bb655df92"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Amenorrhea and Oligomenorrhea</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Females who use levonorgestrel and ethinyl estradiol tablets may experience absence of scheduled (withdrawal) bleeding, even if they are not pregnant. Based on data from the clinical trial of levonorgestrel and ethinyl estradiol tablets, amenorrhea occurred in approximately 0.8% of females during Cycle 1, 1.2% of females during Cycle 2, 3.7% of females during Cycle 3, and 3.4% of females during Cycle 4.</paragraph>
                              <paragraph>Because females using levonorgestrel and ethinyl estradiol tablets will likely have scheduled bleeding only 4 times per year, rule out pregnancy at the time of any missed menstrual period. </paragraph>
                              <paragraph>After discontinuation of levonorgestrel and ethinyl estradiol tablets, amenorrhea or oligomenorrhea may occur, especially if these conditions were pre-existent.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_e7fabba8-6e67-407f-8a2f-540d083224c8">
                     <id root="b582d026-5673-da74-53eb-1823f052fae9"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.10	Depression  </title>
                     <text>
                        <paragraph>Carefully observe females with a history of depression and discontinue levonorgestrel and ethinyl estradiol tablets if depression recurs to a serious degree. Data on the association of COCs with onset of depression or exacerbation of existing depression are limited.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8875c157-10e1-42ef-8a24-40d91fe8ebfa">
                     <id root="f7d2bb1b-9593-a500-ceac-dc0d0396f28a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.11	Malignant Neoplasms </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_be0da94b-792c-4364-a4d4-6ecfa4b844a9">
                           <id root="74991fda-5c38-34fb-244e-74c7bf0da90c"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="italics">Breast Cancer</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Levonorgestrel and ethinyl estradiol tablets are contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml>]</content>.</paragraph>
                              <paragraph>Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (&lt;6 months since last use) and current users with longer duration of COC use <content styleCode="italics">[see <linkHtml href="#ID_3be216ba-ed29-4c04-863b-2e94b75d6583">Postmarketing Experience (6.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_46750e8d-f4b5-410b-8ecb-b91ef14c74e8">
                           <id root="02924d03-2c94-cd52-7fd2-cb145adb958f"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="italics">Cervical Cancer</content>
                              <content styleCode="italics"/>
                           </title>
                           <text>
                              <paragraph>Some studies suggest that COC are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_57a9fe94-958b-4e6a-8dfd-94b4751a8f5c">
                     <id root="be9336b1-7154-0ac3-66fd-b98d7850d07e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.12	Effect on Binding Globulins  </title>
                     <text>
                        <paragraph>The estrogen component of levonorgestrel and ethinyl estradiol tablets may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e89421d6-4f2d-4ffc-ab42-f7bb7c1494ce">
                     <id root="bece81aa-b754-6694-470b-818a855b8ed0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.13	Hereditary Angioedema  </title>
                     <text>
                        <paragraph>In females with hereditary angioedema, exogenous estrogens, including levonorgestrel and ethinyl estradiol tablets, may induce or exacerbate symptoms of hereditary angioedema.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_26cdc66c-f92d-42c2-97f9-467e66a5e733">
                     <id root="bae2e556-a693-9d19-55a7-c135c67b068e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.14	Chloasma  </title>
                     <text>
                        <paragraph>Chloasma may occur with levonorgestrel and ethinyl estradiol tablets use, especially in females with a history of chloasma gravidarum. Advise females with a history of chloasma to avoid exposure to the sun or ultraviolet radiation while taking levonorgestrel and ethinyl estradiol tablets. </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c2d49922-8d97-4abb-a314-725f3879e85e">
               <id root="7063d17c-6950-bb3e-85cb-d29b2bfad660"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Serious cardiovascular events and stroke <content styleCode="italics">[see <linkHtml href="#ID_dcf98049-83de-4597-9cb2-d777f5b0d2ee">Boxed Warning</linkHtml> and <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Vascular events <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Liver disease <content styleCode="italics">[see <linkHtml href="#ID_c2d59193-5664-4c2d-9d45-37dc47ef723e">Warnings and Precautions (5.2)</linkHtml>]</content>
                        </paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥2%) reported during clinical trials were headache, menorrhagia, nausea, dysmenorrhea, acne, migraine, breast tenderness, weight increased, and depression. (<linkHtml href="#ID_0b0ae1cc-5ff6-4444-9a10-bf3c73882381">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Xiromed, LLC at 844-XIROMED (844-947-6633) or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0b0ae1cc-5ff6-4444-9a10-bf3c73882381">
                     <id root="332d4317-77d3-4117-bf32-4dc16832ae51"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trial Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The clinical trial that evaluated the safety and efficacy of levonorgestrel and ethinyl estradiol tablets was a 12-month, randomized, multicenter, open-label study, which enrolled women aged 18 to 40, of whom 456 took at least one dose of levonorgestrel and ethinyl estradiol tablets (345.14 woman-years of exposure) <content styleCode="italics">[see <linkHtml href="#ID_6e1caa88-022d-4e9b-b604-daaaf73b1b95">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Adverse Reactions Leading to Study Discontinuation:</content> 14.9% of the women discontinued from the clinical trial due to an adverse reaction; the most common adverse reactions (≥ 1% of women) leading to discontinuation in the levonorgestrel and ethinyl estradiol tablets group were menorrhagia (5.7%), mood swings (1.9%), weight/appetite increase (1.5%), and acne (1.3%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Common Adverse Reactions (≥ 2% of women):</content> headache (20.6%), menorrhagia (11.6%), nausea (7.5%), dysmenorrhea (5.7%), acne (4.6%), migraine (4.4%), breast tenderness (3.5%), weight increased (3.1%), and depression (2.1%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Serious Adverse Reactions:</content> pulmonary embolus, cholecystitis.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3be216ba-ed29-4c04-863b-2e94b75d6583">
                     <id root="c92357d4-e388-a170-e8ae-cac92f158f41"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2).</paragraph>
                        <paragraph>Three studies compared breast cancer risk between current or recent COC users (&lt;6 months since last use) and never users of COCs (Figure 2). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.</paragraph>
                        <renderMultiMedia ID="id598524082" referencedObject="FD2A99F0-2E93-488B-BA46-EB9F23FB507E">
                           <caption>Figure 2: Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives</caption>
                        </renderMultiMedia>
                        <paragraph>RR = relative risk; OR = odds ratio; HR = hazard ratio. “ever COC” are females with current or past COC use; “never COC use” are females that never used COCs.</paragraph>
                        <paragraph>The following adverse reactions have been identified during post-approval use of levonorgestrel and ethinyl estradiol tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal disorders</content>: abdominal distension, vomiting</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions</content>: chest pain, fatigue, malaise, edema peripheral, pain </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorder:</content> hypersensitivity reactions, including itching, rash, and angioedema</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> blood pressure increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders</content>: muscle spasms, pain in extremity</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders</content>: dizziness, loss of consciousness</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders</content>: insomnia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive and breast disorders</content>: dysmenorrhea</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders</content>: alopecia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular disorders</content>: thrombosis, pulmonary embolism, pulmonary thrombosis</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                     <component>
                        <observationMedia ID="FD2A99F0-2E93-488B-BA46-EB9F23FB507E">
                           <text>Figure 2: Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f1e24648-9980-4bd8-8f4c-cc3ef8191704">
               <id root="6119a262-77bb-7548-5d35-20fb3c48cf85"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>The sections below provide information on substances for which data on drug interactions with COCs are available. There is little information available about the clinical effect of most drug interactions that may affect COCs. However, based on the known pharmacokinetic effects of these drugs, clinical strategies to minimize any potential adverse effect on contraceptive effectiveness or safety are suggested.</paragraph>
                  <paragraph>Consult the approved product labeling of all concurrently used drugs to obtain further information about interactions with COCs or the potential for metabolic enzyme or transporter system alterations.</paragraph>
                  <paragraph>No drug-drug interaction studies were conducted with levonorgestrel and ethinyl estradiol tablets.</paragraph>
               </text>
               <effectiveTime value="20240715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Enzyme inducers (e.g., CYP3A4): May decrease the effectiveness of levonorgestrel and ethinyl estradiol tablets or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with levonorgestrel and ethinyl estradiol tablets. (<linkHtml href="#ID_2c7cc109-a8e3-487a-9d01-8f2db8beab26">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_2c7cc109-a8e3-487a-9d01-8f2db8beab26">
                     <id root="e325d8e3-efe8-327f-7956-beaa50fa9b7a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1	Effects of Other Drugs on Combined Oral Contraceptives </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_320c7e02-47a5-46fe-88e0-277e7810f2a4">
                           <id root="f3c43575-404c-bc42-3cd4-2b99231d11f9"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Substances decreasing the plasma concentrations of COCs and potentially diminishing the efficacy of COCs:</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Table 5 includes substances that demonstrated an important drug interaction with levonorgestrel and ethinyl estradiol tablets.</paragraph>
                              <table width="100%">
                                 <caption>Table 5: Significant Drug Interactions Involving Substances That Affect COCs</caption>
                                 <col width="28%"/>
                                 <col width="72%"/>
                                 <tbody>
                                    <tr>
                                       <td colspan="2" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>Metabolic Enzyme Inducers</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="top">
                                          <paragraph>Clinical effect </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <list listType="unordered">
                                             <item>
                                                <paragraph>Concomitant use of COCs with metabolic enzyme inducers may decrease the plasma concentrations of the estrogen and/or progestin component of COCs.</paragraph>
                                             </item>
                                             <item>
                                                <paragraph>Decreased exposure of the estrogen and/or progestin component of COCs may potentially diminish the effectiveness of COCs and may lead to contraceptive failure or an increase in breakthrough bleeding.</paragraph>
                                             </item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="top">
                                          <paragraph>Prevention or management </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <list listType="unordered">
                                             <item>
                                                <paragraph>Counsel females to use an alternative method of contraception or a backup method when enzyme inducers are used with COCs.</paragraph>
                                             </item>
                                             <item>
                                                <paragraph>Continue backup contraception for 28 days after discontinuing the enzyme inducer to maintain contraceptive reliability.</paragraph>
                                             </item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="top">
                                          <paragraph>Examples </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <paragraph>Aprepitant, barbiturates, bosentan, carbamazepine, efavirenz, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, rifabutin, rufinamide, topiramate, products containing St. John’s wort<sup>a</sup>, and certain protease inhibitors (see separate section on protease inhibitors below).</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="2" styleCode="Rrule Lrule Botrule" valign="top">
                                          <paragraph>Colesevelam</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule" valign="top">
                                          <paragraph>Clinical effect </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <list listType="unordered">
                                             <item>
                                                <paragraph>Concomitant use of COCs with colesevelam significantly decreases systemic exposure of ethinyl estradiol <content styleCode="italics">[see <linkHtml href="#ID_a4b781d1-9ea0-4b1b-82d1-da22e7804500">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                                             </item>
                                             <item>
                                                <paragraph>Decreased exposure of the estrogen component of COCs may potentially reduce contraceptive efficacy or result in an increase in breakthrough bleeding, depending on the strength of ethinyl estradiol in the COC.</paragraph>
                                             </item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>Prevention or management </paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule" valign="middle">
                                          <paragraph>Administer 4 or more hours apart to attenuate this drug interaction. </paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph> <sup>a</sup> Induction potency of St. John’s wort may vary widely based on preparation.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_fb61d58e-dbfe-4559-8b67-df1a2602b351">
                           <id root="13c93c4f-5a11-4082-fdb8-ae3adecb6a96"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Substances increasing the systemic exposure of COCs:</content>
                           </title>
                           <text>
                              <paragraph>Co-administration of atorvastatin or rosuvastatin and certain COCs containing ethinyl estradiol (EE) increase AUC values for EE by approximately 20-25%. Ascorbic acid and acetaminophen may increase systemic exposure of EE possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase systemic exposure of estrogen and/or progestin component of COCs.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_1fc7bd61-d4d5-42df-934a-208b2ee0926b">
                           <id root="40cde9c1-89a0-0081-9c92-5f127a9baac1"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Human immunodeficiency virus (HIV)/ Hepatitis C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors:</content>
                           </title>
                           <text>
                              <paragraph>Significant decreases in systemic exposure of the estrogen and/or progestin have been noted when COCs are co-administered with some HIV protease inhibitors (e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or some HCV protease inhibitors (e.g., boceprevir and telaprevir) and some non-nucleosidase reverse transcriptase inhibitors (e.g., nevirapine).</paragraph>
                              <paragraph>In contrast, significant increases in systemic exposure of the estrogen and/or progestin have been noted when COCs are co-administered with certain other HIV protease inhibitors (e.g., indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (e.g., etravirine).</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_10aca657-0a89-4cfc-a3d3-333f8c113d6e">
                     <id root="3af31591-f9f0-9528-354d-47860d8687dd"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.2	Effects of Combined Oral Contraceptives on Other Drugs </title>
                     <text>
                        <paragraph>Table 6 provides significant drug interaction information for drugs co-administered with levonorgestrel and ethinyl estradiol tablets.</paragraph>
                        <table width="100%">
                           <caption>Table 6: Significant Drug Interaction Information for Drugs Co-Administered With COCs</caption>
                           <col width="30%"/>
                           <col width="70%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Lamotrigine</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>Clinical effect </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <paragraph>Concomitant use of COCs with lamotrigine may significantly decrease systemic exposure of lamotrigine due to induction of lamotrigine glucuronidation <content styleCode="italics">[See <linkHtml href="#ID_a4b781d1-9ea0-4b1b-82d1-da22e7804500">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                                       </item>
                                       <item>
                                          <paragraph>Decreased systemic exposure of lamotrigine may reduce seizure control.</paragraph>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>Prevention or management </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>Dose adjustment may be necessary. Consult the approved product labeling for lamotrigine.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>Clinical effect </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>Concomitant use of COCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin <content styleCode="italics">[see <linkHtml href="#ID_57a9fe94-958b-4e6a-8dfd-94b4751a8f5c">Warnings and Precautions (5.12)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="middle">
                                    <paragraph>Prevention or management </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="middle">
                                    <paragraph>The dose of replacement thyroid hormone or cortisol therapy may need to be increased. Consult the approved product labeling for the therapy in use <content styleCode="italics">[see <linkHtml href="#ID_57a9fe94-958b-4e6a-8dfd-94b4751a8f5c">Warnings and Precautions (5.12)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Other Drugs</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule" valign="top">
                                    <paragraph>Clinical effect </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                    <paragraph>Concomitant use of COCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. Concomitant use with ethinyl estradiol-containing COCs may increase systemic exposure of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole). </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>Prevention or management </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                    <paragraph>The dosage of drugs that can be affected by this interaction may need to be increased. Consult the approved product labeling for the concomitantly used drug. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a7dd252c-3ce5-4ce4-90c4-86acd90cae0e">
                     <id root="c7bfc6f4-81b0-962f-2946-da636daceb31"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.3 Concomitant Use with Hepatitis C Virus (HCV) Combination Therapy – Liver Enzyme Elevation  </title>
                     <text>
                        <paragraph>Co-administration of levonorgestrel and ethinyl estradiol tablets with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to potential for ALT elevations <content styleCode="italics">[see <linkHtml href="#ID_37935806-ae24-4806-ad81-1f2f4498f8ba">Warning and Precautions (5.3)</linkHtml>]</content>. Co-administration of levonorgestrel and ethinyl estradiol tablets and glecaprevir/pibrentasvir is not recommended due to potential for ALT elevations.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0170e7b7-add5-4b3c-9a05-2a2392ff1095">
                     <id root="75278880-ee45-fa83-094e-3a50c7da2878"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.4 Interactions with Laboratory Tests</title>
                     <text>
                        <paragraph>The use of COCs may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_dadc0245-0e47-45ab-a23b-6398edbbef8d">
               <id root="f8f9e46f-cd83-91f8-1e91-7e1077e8f5ac"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20241015"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <paragraph>Pregnancy: Discontinue if pregnancy occurs. (<linkHtml href="#ID_f243fee4-987a-4281-b7d5-692266d4f09d">8.1</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Lactation: Advise use of another contraceptive method; levonorgestrel and ethinyl estradiol tablets; may decrease milk production. (<linkHtml href="#ID_c65b9b36-8eaa-4097-8082-bfc00ae846de">8.2</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f243fee4-987a-4281-b7d5-692266d4f09d">
                     <id root="0be37125-6434-f8af-cc67-d59a2585d92c"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_aefcf1f2-624c-4f42-ac41-37f451179bdb">
                           <id root="c16773f4-6054-0e4e-8da4-eb69505de34b"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>There is no use for contraception in pregnancy; therefore, levonorgestrel and ethinyl estradiol tablets should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to COCs before conception or during early pregnancy.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_c65b9b36-8eaa-4097-8082-bfc00ae846de">
                     <id root="4656e558-df79-fa43-7929-e9ccfa859f09"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_1485f5a2-d1e9-4b77-a086-2a1315590f1d">
                           <id root="f50be1f8-b084-5bbd-b8e1-36e3c1276a25"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breastfeeding <content styleCode="italics">[see <linkHtml href="#ID_a3cbce58-33da-4eb7-800a-198a65a51b61">Dosage and Administration (2.1)</linkHtml>]</content>. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for levonorgestrel and ethinyl estradiol tablets and any potential adverse effects on the breastfed child from levonorgestrel and ethinyl estradiol tablets or the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_d7468968-6c85-44ee-9a73-06a2f844e347">
                     <id root="91de18c1-946f-4c63-68e4-aba0c9938e4c"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and efficacy of levonorgestrel and ethinyl estradiol tablets have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal adolescents under the age of 18 as for users 18 years and older. Use of levonorgestrel and ethinyl estradiol tablets before menarche is not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_75139e61-f2f0-432e-a93b-6b7b94d605c5">
                     <id root="df9ddc12-83a0-abff-dfab-c8f6deff432f"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Levonorgestrel and ethinyl estradiol tablets have not been studied in postmenopausal women and is not indicated in this population.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b040c6ef-c716-42df-b060-58366b89a3bc">
                     <id root="7379bfe0-d718-42ce-41e1-94c3da850236"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6	Hepatic Impairment </title>
                     <text>
                        <paragraph>The pharmacokinetics of levonorgestrel and ethinyl estradiol tablets have not been studied in subjects with hepatic impairment. However, COCs may be poorly metabolized in patients with hepatic impairment. Levonorgestrel and ethinyl estradiol tablets are contraindicated in females with acute hepatitis or severe decompensated cirrhosis <content styleCode="italics">[see <linkHtml href="#ID_82cc12e4-8e39-47b6-a7be-e61268e5fb6e">Contraindications (4)</linkHtml> and <linkHtml href="#ID_c2d59193-5664-4c2d-9d45-37dc47ef723e">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5f743b9d-307a-4879-83bd-6e45dc633ec9">
               <id root="db20d817-cee8-5f36-0a17-fe58dc42eeee"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.</paragraph>
               </text>
               <effectiveTime value="20240715"/>
            </section>
         </component>
         <component>
            <section ID="ID_19852196-2b8b-4615-a571-f58442175cad">
               <id root="3aaa9003-1f81-a83e-aa08-8d29e61b23c3"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Introvale (Levonorgestrel and Ethinyl Estradiol Tablets, USP) is an extended-cycle combination oral contraceptive consisting of 84 white to off-white active tablets each containing 0.15 mg of levonorgestrel, a synthetic progestin and 0.03 mg of ethinyl estradiol, an estrogen, and 7 green inert tablets (without hormones).</paragraph>
                  <paragraph>The structural formulas for the active components are:</paragraph>
                  <renderMultiMedia ID="id-1158763306" referencedObject="ID_61092016-9764-434f-b7b7-ae41509c75d3"/>
                  <paragraph>Levonorgestrel is chemically 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-, (-)-.</paragraph>
                  <renderMultiMedia ID="id-626787574" referencedObject="ID_2527622b-2233-4073-b470-f77a68ccfa2c"/>
                  <paragraph>Ethinyl Estradiol is 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-.</paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Each white to off-white active tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate and polacrilin potassium.</paragraph>
                     </item>
                     <item>
                        <paragraph>Each green inert tablet contains the following inactive ingredients: FD&amp;C Blue No. 1 Aluminum Lake, lactose monohydrate, magnesium stearate, polacrilin potassium and yellow oxide of iron.</paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240715"/>
               <component>
                  <observationMedia ID="ID_61092016-9764-434f-b7b7-ae41509c75d3">
                     <text>Levonorgestrel Stuctural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_2527622b-2233-4073-b470-f77a68ccfa2c">
                     <text>Ethinyl Estradiol Stuctural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3423ec3d-109c-46d0-b1c7-899834ba16db">
               <id root="d113fbdc-8677-fcbf-3666-303e05267494"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20240715"/>
               <component>
                  <section ID="ID_e83c9f11-d273-48ed-8e3d-f9b4354cb56a">
                     <id root="4559c9bb-393b-5c4c-658f-d2f17ee39765"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>COCs prevent pregnancy primarily by suppressing ovulation.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_40cdf9cf-4cef-4f85-9173-77e92532627e">
                     <id root="0d32e97c-bcd4-011f-dddc-3b9c9e5ef893"/>
                     <code code="43681-6" displayName="PHARMACODYNAMICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>No specific pharmacodynamic studies were conducted with Introvale.</paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a4b781d1-9ea0-4b1b-82d1-da22e7804500">
                     <id root="59101bdb-bb7a-a412-dd1b-aa1cd0b9ad2f"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics </title>
                     <effectiveTime value="20240715"/>
                     <component>
                        <section ID="ID_0d27de36-a342-41d9-9d62-9679485f151c">
                           <id root="dc18c41c-3102-cabd-c33e-666dc4d463c4"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Absorption</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>No specific investigation of the absolute bioavailability of Introvale in humans has been conducted. However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability nearly 100%) and is not subject to first-pass metabolism. EE is rapidly and almost completely absorbed from the gastrointestinal tract but, due to first-pass metabolism in gut mucosa and liver, the bioavailability of EE is approximately 43%.</paragraph>
                              <paragraph>Following continuous dosing with once-daily administration of Introvale tablets, plasma concentrations of levonorgestrel and EE reached steady-state within 7 days. The mean plasma pharmacokinetic parameters for Introvale under fasting conditions in normal healthy women following once-daily administration of one levonorgestrel/EE combination tablet for 10 days are summarized in Table 7.</paragraph>
                              <table width="100%">
                                 <caption>Table 7: Mean ±SD Pharmacokinetic Parameters Under Fasting Conditions in Healthy Women Following 10 Days Administration of One Tablet of Introvale (n=44)</caption>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="16%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <col width="16%"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Analyte</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC<sub>0-24</sub>
                                             </content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C<sub>max</sub>
                                             </content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C<sub>min</sub>
                                             </content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C<sub>avg</sub>
                                                <sup>a</sup>
                                             </content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">T<sub>max</sub>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Lrule Botrule" valign="top">
                                          <paragraph>Levonorgestrel</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <paragraph>54.6 ± 16.5</paragraph>
                                          <paragraph>ng*hr/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <paragraph>5.0 ± 1.5 ng/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <paragraph>1.6 ± 0.5</paragraph>
                                          <paragraph>ng/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <paragraph>2.3 ± 0.7</paragraph>
                                          <paragraph>ng/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule" valign="top">
                                          <paragraph>1.4 ± 0.7 hours</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>Ethinyl estradiol</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>935.5 ± 346.9</paragraph>
                                          <paragraph>pg*hr/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>106.1 ± 41.2</paragraph>
                                          <paragraph>pg/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>18.5 ± 9.4</paragraph>
                                          <paragraph>pg/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>38.9 ± 14.4</paragraph>
                                          <paragraph>pg/mL</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule" valign="top">
                                          <paragraph>1.6 ± 0.6</paragraph>
                                          <paragraph>hours</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <sub> </sub>
                                 <sup>a</sup> C<sub>avg</sub> = AUC<sub>0-24/24</sub>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                           <component>
                              <section ID="ID_66c91c1f-b5b9-4f28-a39a-d85a41b5ff42">
                                 <id root="34cf69a1-6e10-22aa-2965-adc21aff749d"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>Food Effect </title>
                                 <text>
                                    <paragraph>The effect of food on the rate and the extent of levonorgestrel and EE absorption following oral administration of Introvale has not been evaluated.</paragraph>
                                 </text>
                                 <effectiveTime value="20240715"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_d889220f-7fef-4194-b9f4-8026f1e7b8ee">
                           <id root="6b8738ad-4998-3133-fa1c-1ea1ccc14ef7"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Distribution</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>The apparent volume of distribution of levonorgestrel and EE are reported to be approximately 1.8 L/kg and 4.3 L/kg, respectively. Levonorgestrel is about 97.5 - 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin. EE is about 95 - 97% bound to serum albumin. EE does not bind to SHBG, but induces SHBG synthesis, which leads to decreased levonorgestrel clearance.</paragraph>
                              <paragraph>Following repeated daily dosing of levonorgestrel/EE oral contraceptives, levonorgestrel plasma concentrations accumulate more than predicted based on single-dose pharmacokinetics, due in part, to increased SHBG levels that are induced by EE, and a possible reduction in hepatic metabolic capacity.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_8fa2b1e6-64ab-4c31-936f-b2989212aeb1">
                           <id root="8c5d8a92-9fdb-8bf0-ac07-09438d84964f"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Metabolism</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate and to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3α,5β- tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α,5α- tetrahydrolevonorgestrel and 16β-hydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.</paragraph>
                              <paragraph>First-pass metabolism of EE involves formation of EE-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of the remaining untransformed EE by hepatic cytochrome P-450 3A4 (CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the variation in rates of EE hydroxylation. Hydroxylation at the 4-, 6-, and 16- positions may also occur, although to a much lesser extent than 2-hydroxylation. The various hydroxylated metabolites are subject to further methylation and/or conjugation.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_480b7413-f005-4213-84b5-bcae7afde012">
                           <id root="0cb54ff9-ac36-91ac-c17c-4dc0bb34fcc1"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Excretion</content>
                              <content styleCode="underline"/>
                           </title>
                           <text>
                              <paragraph>About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates. The terminal elimination half-life for levonorgestrel after a single dose of Introvale was about 30 hours.</paragraph>
                              <paragraph>EE is excreted in the urine and feces as glucuronide and sulfate conjugates, and it undergoes enterohepatic recirculation. The terminal elimination half-life of EE after a single dose of Introvale was found to be about 15 hours.</paragraph>
                           </text>
                           <effectiveTime value="20240715"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_54c9ffe5-eb6b-4599-8d89-cb9ef1746210">
               <id root="94c14549-3846-75fd-f354-ccb3fb9606bc"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20240715"/>
               <component>
                  <section ID="ID_11a09ce5-6c1a-46bf-8ef8-4e34e6376e8e">
                     <id root="f17afb8c-30fc-4581-1df5-e5a7728cbb91"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">See <linkHtml href="#ID_c2d59193-5664-4c2d-9d45-37dc47ef723e">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_8875c157-10e1-42ef-8a24-40d91fe8ebfa">5.11)</linkHtml>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240715"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6e1caa88-022d-4e9b-b604-daaaf73b1b95">
               <id root="f0c86d44-29d1-2a65-52a4-076d695cf4d2"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>In a 12-month, multicenter, randomized, open-label clinical trial, 456 women aged 18-40 were studied to assess the safety and efficacy of levonorgestrel and ethinyl estradiol tablets, completing 809 91-day cycles of exposure. The racial demographic of those enrolled was: Caucasian (77%), African-American (11%), Hispanic (7%), Asian (2%), and Other (3%).</paragraph>
                  <paragraph>There were no exclusions for body mass index (BMI) or weight. The weight range of those women treated was 84 to 304 pounds, with a mean weight of 157 pounds and a median weight of 147 pounds. Among the women in the trial, 63% were current or recent hormonal contraceptive users, 29% were prior users (who had used hormonal contraceptives in the past but not in the 6 months prior to enrollment), and 8% were new starts.</paragraph>
                  <paragraph>The pregnancy rate (Pearl Index [PI]) in the 397 women aged 18-35 years was 1.98 pregnancies per 100 women-years of use (95% CI: 0.54 to 5.03), based on 4 pregnancies that occurred after the onset of treatment and within 14 days after the last combination pill. Cycles in which conception did not occur, but which included the use of back-up contraception, were not included in the calculation of the PI.</paragraph>
               </text>
               <effectiveTime value="20240715"/>
            </section>
         </component>
         <component>
            <section ID="ID_0bf2bba3-7eaa-468e-93b1-eb164a24ed25">
               <id root="9c4a6d1c-b0d7-5f2e-4692-0d6efb9dba50"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <paragraph>Introvale (Levonorgestrel and Ethinyl Estradiol Tablets, USP) 0.15 mg/0.03 mg is available as round, biconvex, unscored tablets, packaged in a carton of 3 pouches (NDC 70700-208-88); each pouch (NDC 70700-208-87) contains Extended-Cycle Tablet Blister Pack of 91 tablets, each containing a 13-week supply of tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>84 white to off-white tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol: debossed with <content styleCode="bold">212</content> on the one side and plain on the other side</paragraph>
                     </item>
                     <item>
                        <paragraph>7 green inert tablets debossed with <content styleCode="bold">279</content> on the one side and plain on the other side</paragraph>
                     </item>
                  </list>
                  <paragraph>Carton of 3 pouches     NDC 70700-208-88</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage and Handling</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Store at 20° to 25° C (68° to 77° F). [See USP Controlled Room Temperature.]</paragraph>
                     </item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <paragraph>Protect from light.</paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240715"/>
            </section>
         </component>
         <component>
            <section ID="ID_500e2f6f-646a-43d8-a333-a19f1471b9c4">
               <id root="c3ee4d88-c023-4042-0af2-475538d3bcdf"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#ID_61b57102-1221-4965-a546-263be49b36a8">Patient Information</linkHtml> and <linkHtml href="#ID_79712ad6-f2aa-4fb6-938d-f0cdd1b609c2">Instructions for Use</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cigarette Smoking </content>
                  </paragraph>
                  <paragraph>Cigarette smoking increases the risk of serious cardiovascular events from COC use. Women who are over 35 years old and smoke should not use Introvale <content styleCode="italics">[see <linkHtml href="#ID_dcf98049-83de-4597-9cb2-d777f5b0d2ee">Boxed Warning</linkHtml> and <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Venous Thromboembolism </content>
                  </paragraph>
                  <paragraph>The increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC <content styleCode="italics">[see <linkHtml href="#ID_14261716-6488-49a1-9bee-201941549417">Warnings and Precautions (5.1)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Use During Pregnancy</content>
                  </paragraph>
                  <paragraph>Instruct females to stop further intake of Introvale if pregnancy is confirmed during treatment.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Sexually Transmitted Infections </content>
                  </paragraph>
                  <paragraph>Introvale does not protect against HIV-infection (AIDS) and other sexually transmitted infections.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing and Missed Pill Instructions </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Patients should take one tablet daily by mouth at the same time every day <content styleCode="italics">[see <linkHtml href="#ID_a3cbce58-33da-4eb7-800a-198a65a51b61">Dosage and Administration (2.1)</linkHtml>]. </content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Instruct patients what to do in the event tablets are missed. See <content styleCode="bold">“What should I do if I miss any Introvale pills”</content> section of FDA-Approved Instructions for Use <content styleCode="italics">[see <linkHtml href="#ID_19f47927-4b29-47e5-8b28-c9f3b228f38a">Dosage and Administration (2.3)</linkHtml>]. </content>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Need for Additional Contraception </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Postpartum females who start Introvale who have not yet had a period when they start Introvale need to use an additional method of contraception until they have taken a white to off-white tablet for 7 consecutive days <content styleCode="italics">[see <linkHtml href="#ID_a3cbce58-33da-4eb7-800a-198a65a51b61">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                     </item>
                     <item>
                        <paragraph>There is a need for a back-up or alternative method of contraception when enzyme inducers are used with Introvale <content styleCode="italics">[see <linkHtml href="#ID_2c7cc109-a8e3-487a-9d01-8f2db8beab26">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation </content>
                  </paragraph>
                  <paragraph>Introvale may reduce breast milk production. This is less likely to occur if breastfeeding is well established. When possible, nursing women should use other methods of contraception until they have discontinued breastfeeding <content styleCode="italics">[see <linkHtml href="#ID_c65b9b36-8eaa-4097-8082-bfc00ae846de">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Amenorrhea and Possible Symptoms of Pregnancy </content>
                  </paragraph>
                  <paragraph>Amenorrhea may occur. Because women using Introvale will likely have scheduled bleeding only 4 times per year, advise women to contact their health care provider in the event of amenorrhea with symptoms of pregnancy such as morning sickness or unusual breast tenderness <content styleCode="italics">[see <linkHtml href="#ID_dec4fdbc-96f8-44b8-ae0a-6d0a8c69f31a">Warnings and Precautions (5.9)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Depression </content>
                  </paragraph>
                  <paragraph>Depressed mood and depression may occur. Women should contact their healthcare provider if mood changes and depressive symptoms occur, including shortly after initiating the treatment <content styleCode="italics">[see <linkHtml href="#ID_e7fabba8-6e67-407f-8a2f-540d083224c8">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20240715"/>
            </section>
         </component>
         <component>
            <section ID="ID_61b57102-1221-4965-a546-263be49b36a8">
               <id root="6d89e9bd-d02a-4d0a-64ff-17f35e946f68"/>
               <code code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>FDA-approved Patient Labeling </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PATIENT INFORMATION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Introvale<sup>®</sup> (Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg)</content>
                  </paragraph>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">WARNING TO WOMEN WHO SMOKE</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not use Introvale if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about Introvale?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not use Introvale if you smoke cigarettes and are over 35 years old.</content> Smoking increases your risk of serious cardiovascular side effects from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is Introvale?</content>
                  </paragraph>
                  <paragraph>Introvale is a birth control pill (oral contraceptive) used by women to prevent pregnancy. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called levonorgestrel. Introvale does <content styleCode="bold">not </content>protect against HIV infections (AIDS) and other sexually transmitted infections.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How does Introvale work for contraception?</content>
                  </paragraph>
                  <paragraph>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.</paragraph>
                  <paragraph>Based on the results of clinical studies, about 1 to 5 out of 100 women may get pregnant during the first year they use Introvale.</paragraph>
                  <paragraph>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</paragraph>
                  <renderMultiMedia ID="id1867864152" referencedObject="D643AFD8-79DF-4769-BD4C-48DA028EB022"/>
                  <paragraph>
                     <content styleCode="bold">Who should not take Introvale?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take Introvale if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>smoke and are over 35 years of age</paragraph>
                     </item>
                     <item>
                        <paragraph>have or had blood clots in your arms, legs, lungs, or eyes</paragraph>
                     </item>
                     <item>
                        <paragraph>had a stroke</paragraph>
                     </item>
                     <item>
                        <paragraph>had a heart attack</paragraph>
                     </item>
                     <item>
                        <paragraph>have certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart</paragraph>
                     </item>
                     <item>
                        <paragraph>have or had a problem with your blood that makes it clot more than normal</paragraph>
                     </item>
                     <item>
                        <paragraph>have high blood pressure that cannot be controlled by medicine or have high blood pressure with blood vessels problems</paragraph>
                     </item>
                     <item>
                        <paragraph>have diabetes</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>o</caption>and are over the age of 35 </item>
                           <item>
                              <caption>o</caption>with high blood pressure</item>
                           <item>
                              <caption>o</caption>with kidney, eye, nerve, or blood vessel damage </item>
                           <item>
                              <caption>o</caption>for more than 20 years </item>
                        </list>
                     </item>
                     <item>
                        <paragraph>have certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or any migraine headaches if you are over 35 years of age</paragraph>
                     </item>
                     <item>
                        <paragraph>have or had breast cancer</paragraph>
                     </item>
                     <item>
                        <paragraph>have liver problems, including liver tumors</paragraph>
                     </item>
                     <item>
                        <paragraph>have any unexplained vaginal bleeding</paragraph>
                     </item>
                     <item>
                        <paragraph>take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may increase levels of the liver enzyme “alanine aminotransferase” (ALT) in the blood.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If any of these conditions happen to you while you are taking Introvale, stop taking Introvale right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking Introvale.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my healthcare provider before taking Introvale?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>are pregnant or think you may be pregnant</paragraph>
                     </item>
                     <item>
                        <paragraph>are scheduled for surgery. Introvale may increase your risk of blood clots after surgery. You should stop taking Introvale at least 4 weeks before you have surgery and not restart Introvale until at least 2 weeks after your surgery.</paragraph>
                     </item>
                     <item>
                        <paragraph>are depressed now or have been depressed in the past</paragraph>
                     </item>
                     <item>
                        <paragraph>had yellowing of your skin or eyes (jaundice) caused by pregnancy (cholestasis of pregnancy)</paragraph>
                     </item>
                     <item>
                        <paragraph>are breastfeeding or plan to breastfeed. Introvale may decrease the amount of breast milk you make. A small amount of the hormones in Introvale may pass into your breast milk. Talk to your healthcare provider about the best birth control method for you while breastfeeding.</paragraph>
                     </item>
                  </list>
                  <paragraph>Tell your healthcare provider if you have ever had any of the conditions listed in, <content styleCode="bold">“Who should not take Introvale</content>” <content styleCode="bold">above</content>. Your healthcare provider may recommend another method of birth control.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins and herbal supplements.</paragraph>
                  <paragraph>Introvale may affect the way other medicines work, and other medicines may affect how well Introvale works.</paragraph>
                  <paragraph>Some medicines and herbal products may make birth control pills less effective, including:</paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>barbiturates</paragraph>
                     </item>
                     <item>
                        <paragraph>bosentan</paragraph>
                     </item>
                     <item>
                        <paragraph>carbamazepine</paragraph>
                     </item>
                     <item>
                        <paragraph>felbamate</paragraph>
                     </item>
                     <item>
                        <paragraph>griseofulvin</paragraph>
                     </item>
                     <item>
                        <paragraph>oxcarbazepine</paragraph>
                     </item>
                     <item>
                        <paragraph>phenytoin</paragraph>
                     </item>
                     <item>
                        <paragraph>rifampin</paragraph>
                     </item>
                     <item>
                        <paragraph>St. John’s wort</paragraph>
                     </item>
                     <item>
                        <paragraph>topiramate</paragraph>
                     </item>
                  </list>
                  <paragraph>Use a back-up or alternative birth control method when you take medicines that may make birth control pills less effective. </paragraph>
                  <paragraph>Birth control pills may interact with lamotrigine, an anticonvulsant used for epilepsy. This may increase the risk of seizures, so your physician may need to adjust the dose of lamotrigine.</paragraph>
                  <paragraph>Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take Introvale?</content>
                  </paragraph>
                  <paragraph>Read the<content styleCode="bold"> Instructions for Use </content>at the end of this Patient Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the most serious risks of taking Introvale?</content>
                  </paragraph>
                  <paragraph>Like pregnancy, Introvale may cause serious side effects, including blood clots in your lungs, heart attack, or a stroke that may lead to death. Some other examples of serious blood clots include blood clots in the legs or eyes. Serious blood clots can happen especially if you smoke, are obese, or are older than 35 years of age. Serious blood clots are more likely to happen when you:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>o</caption>first start taking birth control pills</item>
                     <item>
                        <caption>o</caption>restart the same or different birth control pills after not using them for a month or more</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Call your healthcare provider or go to a hospital emergency room right away if you have:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>o</caption>leg pain that will not go away </item>
                     <item>
                        <caption>o</caption>sudden severe shortness of breath </item>
                     <item>
                        <caption>o</caption>sudden change in vision or blindness </item>
                     <item>
                        <caption>o</caption>chest pain </item>
                     <item>
                        <caption>o</caption>a sudden, severe headache unlike your usual headaches </item>
                     <item>
                        <caption>o</caption>weakness or numbness in your arm or leg </item>
                     <item>
                        <caption>o</caption>trouble speaking </item>
                     <item>
                        <caption>o</caption>yellowing of your skin or eyes </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Other serious side effects include:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>
                           <content styleCode="bold">liver problems, including:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>o</caption>rare liver tumors</item>
                           <item>
                              <caption>o</caption>jaundice (cholestasis), especially if you previously had cholestasis of pregnancy. </item>
                        </list>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">high blood pressure.</content> You should see your healthcare provider to check your blood pressure regularly.</paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">gallbladder problems</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">changes in the sugar and fat (cholesterol and triglycerides) levels in your blood</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">new or worsening headaches including migraine headaches</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">irregular or unusual vaginal bleeding and spotting between your menstrual periods, especially during the first 3 months of taking Introvale.</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">depression, </content>especially if you have had depression in the past. Call your healthcare provider immediately if you have any thoughts of harming yourself.</paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">possible cancer in your breast and cervix</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">swelling of your skin especially around your mouth, eyes, and in your throat (angioedema).</content> Call your healthcare provider if you have a swollen face, lips, mouth tongue or throat, which may lead to difficulty swallowing or breathing. Your chance of having angioedema is higher is you have a history of angioedema.</paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">dark patches of skin around your forehead, nose, cheeks and around your mouth, especially during pregnancy (chloasma).</content> Women who tend to get chloasma should avoid spending a long time in sunlight, tanning booths, and under sun lamps while taking Introvale. Use sunscreen if you have to be in the sunlight.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the most common side effects of Introvale?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>headache (migraine)</paragraph>
                     </item>
                     <item>
                        <paragraph>heavier or longer periods, pain with periods</paragraph>
                     </item>
                     <item>
                        <paragraph>nausea</paragraph>
                     </item>
                     <item>
                        <paragraph>acne</paragraph>
                     </item>
                     <item>
                        <paragraph>breast tenderness</paragraph>
                     </item>
                     <item>
                        <paragraph>increase in weight</paragraph>
                     </item>
                  </list>
                  <paragraph>These are not all the possible side effects of Introvale. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What else should I know about taking Introvale?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>If you are scheduled for any lab tests, tell your healthcare provider you are taking Introvale. Certain blood tests may be affected by Introvale.</paragraph>
                     </item>
                     <item>
                        <paragraph>Do not skip any pills, even if you do not have sex often.</paragraph>
                     </item>
                     <item>
                        <paragraph>Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects.</paragraph>
                     </item>
                     <item>
                        <paragraph>You should stop Introvale at least four weeks before you have major surgery and not restart it for at least two weeks after the surgery, due to an increased risk of blood clots.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like Introvale, may decrease the amount of milk you make. A small amount of the pill's hormones pass into breast milk, but this has not caused harmful effects in breastfeeding infants.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like condoms or a spermicide, until you check with your healthcare provider.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How should I store Introvale?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Store Introvale at room temperature between 20°C to 25°C (68°F to 77°F). Protect from light.</paragraph>
                     </item>
                     <item>
                        <paragraph>Keep Introvale and all medicines out of the reach of children.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of Introvale.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Introvale for a condition for which it was not prescribed. Do not give Introvale to other people, even if they have the same symptoms that you have.</paragraph>
                  <paragraph>This Patient Information summarizes the most important information about Introvale. You can ask your pharmacist or healthcare provider for information about Introvale that is written for health professionals.</paragraph>
                  <paragraph>For more information, call Xiromed, LLC at 844-XIROMED (844-947-6633).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do birth control pills cause cancer?</content>
                  </paragraph>
                  <paragraph>It is not known if hormonal birth control pills cause breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use.</paragraph>
                  <paragraph>If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I want to become pregnant?</content>
                  </paragraph>
                  <paragraph>You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I know about my period when taking Introvale?</content>
                  </paragraph>
                  <paragraph>When you take Introvale, which has a 91-day extended dosing cycle, you should have <content styleCode="bold">4 </content>scheduled periods a year (bleeding when you are taking the <content styleCode="bold">7</content> green pills). However, you will probably have more bleeding or spotting between your scheduled periods than if you were using a birth control pill with a 28-day dosing cycle. During the first Introvale 91-day treatment cycle, about <content styleCode="bold">1</content> in <content styleCode="bold">3</content> women may have <content styleCode="bold">20</content> or more days of unplanned bleeding or spotting. This bleeding or spotting tends to decrease with time. <content styleCode="bold">Do not</content> stop taking Introvale because of this bleeding or spotting. If the spotting continues for more than <content styleCode="bold">7</content> days in a row or if the bleeding is heavy, call your healthcare provider.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I miss my scheduled period when taking Introvale?</content>
                  </paragraph>
                  <paragraph>You should consider the possibility that you are pregnant if you miss your scheduled period (no bleeding on the days that you are taking green pills). Since scheduled periods are less frequent when you are taking Introvale, notify your healthcare provider that you have missed your period and that you are taking Introvale. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. It is important that your healthcare provider evaluates you to determine if you are pregnant. Stop taking Introvale if it is determined that you are pregnant.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in Introvale?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredients:</content> Each white to off-white pill contains levonorgestrel and ethinyl estradiol.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>
                  </paragraph>
                  <paragraph>White to off-white pills: Lactose monohydrate, magnesium stearate and polacrilin potassium.</paragraph>
                  <paragraph>Green pills: FD&amp;C Blue No. 1 Aluminum Lake, lactose monohydrate, magnesium stearate, polacrilin potassium and yellow oxide of iron.</paragraph>
               </text>
               <effectiveTime value="20240715"/>
               <component>
                  <observationMedia ID="D643AFD8-79DF-4769-BD4C-48DA028EB022">
                     <text>Patient Information - Chance of Getting Pregnant Estimate</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_79712ad6-f2aa-4fb6-938d-f0cdd1b609c2">
               <id root="e4165430-2290-85d4-0e37-870230038bf4"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions For Use </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Introvale<sup>®</sup> (Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information about taking Introvale</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Take <content styleCode="bold">1</content> pill every day at the same time. Take the pills in the order directed on your pill dispenser.</paragraph>
                     </item>
                     <item>
                        <paragraph>Do not skip your pills, even if you do not have sex often. If you miss pills (including starting the pack late) <content styleCode="bold">you could get pregnant</content>. The more pills you miss, the more likely you are to get pregnant.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you have trouble remembering to take Introvale, talk to your healthcare provider.</paragraph>
                     </item>
                     <item>
                        <paragraph>When you first start taking Introvale, spotting or light bleeding in between your periods may occur. Contact your healthcare provider if this does not go away after a few months.</paragraph>
                     </item>
                     <item>
                        <paragraph>You may feel sick to your stomach (nauseous), especially during the first few months of taking Introvale. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If your nausea does not go away, call your healthcare provider.</paragraph>
                     </item>
                     <item>
                        <paragraph>Missing pills can also cause spotting or light bleeding, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills (see, “<content styleCode="bold">What should I do if I miss any Introvale pills?”</content> below), you could also feel a little sick to your stomach.</paragraph>
                     </item>
                     <item>
                        <paragraph>It is not uncommon to miss a period. However, if you miss a period and have not taken Introvale according to directions, or feel like you may be pregnant, call your healthcare provider. If you have a positive pregnancy test, you should stop taking Introvale.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you have vomiting or diarrhea within <content styleCode="bold">3-4</content> hours of taking a white to off-white pill, take another white to off-white pill as soon as possible. Continue taking one pill a day until the 91-day course is finished.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you have vomiting or diarrhea for more than 1 day, your birth control pills may not work as well. Use an additional birth control method, like condoms or spermicide, until you check with your healthcare provider.</paragraph>
                     </item>
                     <item>
                        <paragraph>Stop taking Introvale at least <content styleCode="bold">4</content> weeks before you have major surgery and do not restart after the surgery without asking your healthcare provider. Be sure to use other forms of contraception (like condoms or spermicide) during this time period.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before you start taking Introvale:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Decide what time of day you want to take your pill. It is important to take it at about the same time every day.</paragraph>
                     </item>
                     <item>
                        <paragraph>Look at your Extended-Cycle Tablet Blister Pack. Your Blister Pack consists of 3 trays with cards that hold 91 individually sealed pills (a 13- week or 91-day cycle). The 91 pills consist of 84 white to off-white and 7 green pills. The cards in trays 1 and 2 each contain 28 white to off-white pills (4 rows of 7 pills). <content styleCode="bold">See Figure A</content>. The card in tray 3 contains 35 pills consisting of 28 white to off-white pills (4 rows of 7 pills) and 7 green pills (1 row of 7 pills). <content styleCode="bold">See Figure B</content>.</paragraph>
                     </item>
                  </list>
                  <renderMultiMedia ID="id1497614329" referencedObject="D11FD1AD-2776-4941-93A0-CF6C2DE86FD0"/>
                  <list listType="unordered">
                     <item>
                        <paragraph>Also find:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>o</caption>Where on the first tray in the pack to start taking pills (upper left corner) and</item>
                           <item>
                              <caption>o</caption>In what order to take the pills (follow the weeks)</item>
                        </list>
                     </item>
                     <item>
                        <paragraph>Be sure you have ready at all times another kind of birth control (such as condoms or spermicide), to use as a back-up in case you miss pills.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">When should I start taking Introvale?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you start taking Introvale and you have not used a hormonal birth control method before:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Take the first white to off-white pill on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the first white to off-white pill that same day.</paragraph>
                     </item>
                     <item>
                        <paragraph>Use another method of birth control (such as condoms or spermicides) as a back-up method if you have sex anytime from the Sunday you start your first white to off-white pill until the next Sunday (first 7 days).</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you have recently given birth and have not yet had a period,</content> use another method of birth control if you have sex (such as condoms and spermicides) as a back-up method until you have taken Introvale for 7 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">If you start taking Introvale and you are switching from another birth control pill:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Start your new Introvale pack on the same day that you would start the next pack of your previous birth control method.</paragraph>
                     </item>
                     <item>
                        <paragraph>Do not continue taking the pills from your previous birth control pack.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you start taking Introvale and previously used a vaginal ring:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Start using Introvale on the day you would have reapplied the next ring.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you start taking Introvale and previously used a transdermal patch:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Start using Introvale on the day you would have started a new cycle (first patch application).</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you start taking Introvale and you are switching from a progestin-only method such as an implant or injection:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Start taking Introvale on the day of removal of your implant, or on the day when you would have had your next injection.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you start taking Introvale and you are switching from an intrauterine device or system (IUD or IUS):</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Start taking Introvale on the day of removal of your IUD or IUS.</paragraph>
                     </item>
                     <item>
                        <paragraph>You do not need back-up contraception if your IUD or IUS is removed on the first day (Day 1) of your period. If your IUD or IUS is removed on any other day, use non-hormonal back-up contraception such as condoms or spermicide for the first <content styleCode="bold">7</content> days that you take Introvale.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep a calendar to track your period: If this is the first time </content>you are taking birth control pills, read, <content styleCode="bold">“When should I start taking Introvale?”</content> above. Follow these instructions for a <content styleCode="bold">Sunday Start.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Instructions for using your Introvale extended-cycle blister pack:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sunday Start:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Take pill <content styleCode="bold">1</content> on the Sunday <content styleCode="bold">after your period starts.</content> To remove your pill from the dispenser, press the pill through the hole in the bottom of the dispenser. <content styleCode="bold">See Figure C.</content>
                        </paragraph>
                     </item>
                  </list>
                  <renderMultiMedia ID="id-624612907" referencedObject="ID_4e58c0d3-340f-4d55-a8cf-d2bf5b59ccbe">
                     <caption>Figure C</caption>
                  </renderMultiMedia>
                  <list listType="unordered">
                     <item>
                        <paragraph>If your period starts on a Sunday, take pill <content styleCode="bold">“1”</content> that same day.</paragraph>
                     </item>
                     <item>
                        <paragraph>Take <content styleCode="bold">1</content> pill at about the same time every day until you have taken the last pill in the blister pack.</paragraph>
                     </item>
                     <item>
                        <paragraph>After taking the last green pill on Day 91 from the pill dispenser, start taking the first white to off-white pill from a new Extended-Cycle Blister Pack on the very next day (this should be a Sunday). Take the first pill in the new pack whether or not you are having your period.</paragraph>
                     </item>
                     <item>
                        <paragraph>Use non-hormonal back-up contraception such as condoms or spermicide for the first <content styleCode="bold">7</content> days of the first cycle that you take Introvale.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I do if I miss any Introvale pills?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you miss 1 white to off-white pill, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Take it as soon as you remember. Take the next pill at your regular time. This means you may take <content styleCode="bold">2</content> pills in <content styleCode="bold">1</content> day.</paragraph>
                     </item>
                     <item>
                        <paragraph>Then continue taking <content styleCode="bold">1</content> pill every day until you finish the pack.</paragraph>
                     </item>
                     <item>
                        <paragraph>You do not need to use a back-up birth control method if you have sex.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you miss 2 white to off-white pills in a row, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Take <content styleCode="bold">2</content> pills on the day you remember and <content styleCode="bold">2</content> pills the next day.</paragraph>
                     </item>
                     <item>
                        <paragraph>Then continue to take <content styleCode="bold">1</content> pill every day until you finish the pack.</paragraph>
                     </item>
                     <item>
                        <paragraph>You could become pregnant if you have sex in the <content styleCode="bold">7</content> days after you miss two pills. You <content styleCode="bold">must</content> use a non-hormonal birth control method (such as a condom or spermicide) as a back-up if you have sex during the first <content styleCode="bold">7 days</content> after you restart your pills.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you miss 3 or more white to off-white pills in a row, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>
                           <content styleCode="bold">Do not</content> take the missed pills. Keep taking <content styleCode="bold">1</content> pill every day until you have completed all of the remaining pills in the pack. For example, if you start taking the pill on Thursday, take the pill under “Thursday” and do not take the missed pills. You may have bleeding during the week following the missed pills.</paragraph>
                     </item>
                     <item>
                        <paragraph>You could become pregnant if you have sex during the days of missed pills or during the first 7 days after restarting your pills. You <content styleCode="bold">must</content> use a non-hormonal birth control method (such as a condom or spermicide) as a back-up when you miss pills and for the first <content styleCode="bold">7 days</content> after you restart your pills. If you do not have your period when you are taking the green pills, call your healthcare provider because you may be pregnant.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you miss any of the 7 green pills:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Throw away the missed pills.</paragraph>
                     </item>
                     <item>
                        <paragraph>Keep taking the scheduled pills until the pack is finished.</paragraph>
                     </item>
                     <item>
                        <paragraph>You do not need a back-up method of birth control.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Finally, if you are still not sure what to do about the pills you have missed</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Use a back-up method anytime you have sex.</paragraph>
                     </item>
                     <item>
                        <paragraph>Keep taking one pill each day until you contact your healthcare provider.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you have any questions or are unsure about the information in this leaflet, call your healthcare provider.</content>
                  </paragraph>
                  <paragraph>This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph/>
                  <paragraph>INTROVALE <sup>®</sup> is a registered trademark of Xiromed Pharma España, S.L.</paragraph>
                  <paragraph/>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xiromed, LLC</content>
                  </paragraph>
                  <paragraph>Florham Park, NJ 07932</paragraph>
                  <paragraph>Made in India</paragraph>
                  <paragraph>Code No.: GUJ-DRUGS/G/28/1297</paragraph>
                  <paragraph>PI-208-00</paragraph>
                  <paragraph>
                     <content styleCode="bold">Revised: 10/2024</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240715"/>
               <component>
                  <observationMedia ID="D11FD1AD-2776-4941-93A0-CF6C2DE86FD0">
                     <text>Instructions for Use Figure A</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_4e58c0d3-340f-4d55-a8cf-d2bf5b59ccbe">
                     <text>Instructions for Use Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_01663c38-134c-4da7-9a0d-e7c1f9e1162e">
               <id root="6d52687a-8338-cdb1-59d2-7c5e612636c3"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.15 mg /0.03 mg </title>
               <text>
                  <paragraph>NDC 70700-208-88</paragraph>
                  <paragraph>RX Only</paragraph>
                  <paragraph>Introvale<sup>®</sup> (Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg)</paragraph>
                  <renderMultiMedia ID="id-887030493" referencedObject="A2E1610F-ADEC-4E72-ADF8-A42489A0EE9A"/>
               </text>
               <effectiveTime value="20240715"/>
               <component>
                  <observationMedia ID="A2E1610F-ADEC-4E72-ADF8-A42489A0EE9A">
                     <text>Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg /0.03 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>